Zolgensma(OAV101 injection) will be introduced to China at a price of $2.125 million per injection, equivalent to about 13.48 million yuan per injection.
SMA is a motor neuron disease similar to the dreaded als. With SMA, motor nerve cells do not work properly and gradually lose control of the body. Eventually, even the breathing and swallowing muscles fail, leading to death. It is reported that the incidence of SMA in newborns is 1 in 6,000 to 1 in 10,000, and about 1 in 40 to 50 people in the general population are SMA disease gene carriers.
Zolgensma was developed by Novartis, the company that inspired the controversy over the sky-high price of the drug in Dying to Die. However, Zolgensma is not only expensive, but also effective. With a single intravenous injection, patients can express SMN proteins in their cells for a long time, achieving long-term remission or even cure. Novartis' CEO has said the drug costs less than current treatments.